TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03511911

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of pelvic floor muscle function through the PHENIX instrument
Description: the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
Study: NCT00935649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PinPointe FootLaser
Description: Medical laser
Study: NCT02829411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workforce Readiness Program
Description: job readiness workshops, organized into ten daily sessions over two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workforce Readiness Program
Description: job readiness workshops, organized into ten daily sessions over two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship education
Description: 25-hours of Within My Reach curriculum and relationship skills education sessions
Study: NCT02623790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (butter)
Description: Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (cheddar cheese)
Description: Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (cream cheese)
Description: Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
Study: NCT02807142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NC 1 cell therapy
Description: All patients will be treated with NC1
Study: NCT04759495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)
Description: rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)
Description: FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
Study: NCT03758833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preimplantation genetic test of embryo by new generation sequencing (NGS)
Description: This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preimplantation genetic test of embryo by new generation sequencing (NGS)
Description: This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single embryo transfer
Description: Transfer of single embryo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single embryo transfer
Description: Transfer of single embryo
Study: NCT00762502

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric contact lens
Description: soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric contact lens
Description: soft contact lens
Study: NCT03758833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double embryo tranfer
Description: Transfer of two embryos
Study: NCT02504502

Intervention type: OTHER
Group type: OTHER
Intervention: enhanced genomic report
Description: a patient-centered version of a genomic results report delivered to patient through the electronic record portal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced genomic report
Description: a patient-centered version of a genomic results report delivered to patient through the electronic record portal
Study: NCT02897219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Therapy
Description: Continuous subcutaneous insulin infusion or multiple daily injections as standard of care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Therapy
Description: Continuous subcutaneous insulin infusion or multiple daily injections as standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Therapy
Description: Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
Study: NCT03376646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort A: Dissolve™
Description: Dissolve™ are to be used in the trial

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cohort A: Resolute™ Integrity
Description: Resolute™ Integrity are to be used in the trial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort B: Dissolve™-2.00mm
Description: Dissolve™ are to be used in the trial
Study: NCT01856478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: intravenous bolus injection, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: oral intake, once daily
Study: NCT02118727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Memantine)
Description: All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Study: NCT02693002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol/Norethindrone acetate
Description: Estradiol/Norethindrone acetate 1mg/0.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive ingredient
Study: NCT05356949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
Study: NCT02699931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric3D
Description: Oral-B 3D with orthodontic head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual
Description: Oral-B orthodontic
Study: NCT02453035

Intervention type: DEVICE
Intervention: PTCA - Desolve Scaffold
Description: Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
Study: NCT04800887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TECNIS Eyhance intraocular lens
Description: Cataract surgery and implantation with extended depth of focus intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal intraocular lens Tecnis ZCB00
Description: Cataract surgery and implantation with monofocal intraocular lens
Study: NCT00986921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 200 mg
Description: mifepristone would be given the day before the procedure
Study: NCT03511911

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
Study: NCT01613638

Intervention type: OTHER
Group type: OTHER
Intervention: meconium samples + maternal self-questionnaire
Description: meconium samples + maternal self-questionnaire
Study: NCT00986921

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: osmotic dilator insertion
Description: osmotic dilators (3-6) would be inserted as usual the day before the procedure
Study: NCT00863252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Orally at 0.75 g bd to 1 g bd for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: angiotensin blockade
Description: Continuation of angiotensin blockade
Study: NCT01559948

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic stabilization exercise
Description: The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stabilization exercise
Description: The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint belt
Description: The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
Study: NCT03661931

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DQPN Validation
Description: We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
Study: NCT00090493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3
Description: vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
Study: NCT03758833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double embryo tranfer
Description: Transfer of two embryos
Study: NCT01493765

Intervention type: OTHER
Intervention: Simulator training with expert scoring
Description: Residents will be trained using surgical simulation
Study: NCT04692402

Intervention type: DEVICE
Group type: OTHER
Intervention: Solitaire™ thrombus retrieval device
Description: After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
Study: NCT01016509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of \<180 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of \<200 mg/dl.
Study: NCT00406978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
Study: NCT00090493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
Description: Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
Study: NCT04424706

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed as type 2 diabetes without atherosclerosis
Description: patients diagnosed as type 2 diabetes without atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed as type 2 diabetes with atherosclerosis
Description: patients diagnosed as type 2 diabetes with atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: people without type 2 diabetes or atherosclerosis
Description: normal people without type 2 diabetes or atherosclerosis
Study: NCT02258373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM+BGM
Description: Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Only
Description: Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
Study: NCT02425878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01832558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02819752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy - Standard Treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy - Standard Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy - Standard Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy - Standard Treatment
Study: NCT01023945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral